Inhibrx Biosciences, Inc.
INBX
$113.06
$0.200.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -5.23% | -0.52% | |||
| Gross Profit | 5.23% | 0.52% | |||
| SG&A Expenses | 44.48% | 2.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.95% | 0.01% | |||
| Operating Income | -3.95% | -0.01% | |||
| Income Before Tax | -9.59% | -1.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -9.60% | -1.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.60% | -1.85% | |||
| EBIT | -3.95% | -0.01% | |||
| EBITDA | -4.07% | -0.10% | |||
| EPS Basic | -9.01% | -1.51% | |||
| Normalized Basic EPS | -9.00% | -1.51% | |||
| EPS Diluted | -9.01% | -1.51% | |||
| Normalized Diluted EPS | -9.00% | -1.51% | |||
| Average Basic Shares Outstanding | 0.54% | 0.33% | |||
| Average Diluted Shares Outstanding | 0.54% | 0.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||